CompletedPhase 2NCT00949182

Sorafenib Tosylate Before and After Hepatic Arterial Chemoembolization With Doxorubicin Hydrochloride and Mitomycin C in Treating Patients With Localized Liver Cancer That Cannot Be Removed by Surgery

Studying Combined hepatocellular carcinoma and cholangiocarcinoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Rutgers, The State University of New Jersey
Principal Investigator
Andrew N. de la Torre, MD
Rutgers University Hospital / St Joseph Medical Center
Intervention
sorafenib tosylate, HACE : Doxorubicin Hydrochloride and Mitomycin C(drug)
Enrollment
20 enrolled
Eligibility
18 years · All sexes
Timeline
20092013

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00949182 on ClinicalTrials.gov

Other trials for Combined hepatocellular carcinoma and cholangiocarcinoma

Additional recruiting or active studies for the same condition.

See all trials for Combined hepatocellular carcinoma and cholangiocarcinoma

← Back to all trials